TRDA Form 4: CFO Sells 1,734 Shares at $5.43 to Cover RSU Taxes

Q: What transaction did Entrada Therapeutics (TRDA) report on this Form 4?

The CFO sold 1,734 shares on 09/02/2025 to cover tax withholding obligations related to vesting RSUs.

Q: At what price were the shares sold according to the Form 4 for TRDA?

Weighted-average price $5.4302 , with reported sale prices ranging between $5.36 and $5.58.

Q: How many TRDA shares does the reporting person beneficially own after the sale?

118,936 shares beneficially owned following the reported transaction.

Q: Why were the shares sold according to the filing?

The shares were sold to cover tax withholding obligations arising from the vesting of previously granted restricted stock units.

Q: Who signed the Form 4 filing for the reporting person?

Signed by Jared Cohen as Attorney-in-Fact with the signature date shown as 09/04/2025.

[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Entrada Therapeutics CFO Kory James sold 1,734 shares on 09/02/2025 to cover tax withholding arising from RSU vesting. The weighted-average price for the sales was $5.4302, with transaction prices reported between $5.36 and $5.58. After the sale, the reporting person beneficially owned 118,936 shares, held directly. The Form 4 was filed indicating the sale was to satisfy withholding obligations tied to previously granted restricted stock units.

Positive

None.

Negative

Officer disposed of 1,734 common shares, reducing direct beneficial ownership from prior levels to 118,936 shares.

Insights

TL;DR: Routine tax-withholding sale by a named officer; small absolute volume and no new derivative positions disclosed.

The Form 4 shows a single non-derivative disposition of 1,734 common shares by the Chief Financial Officer on 09/02/2025 at a weighted-average price of $5.4302, with prices ranging $5.36 to $5.58. The filing states these shares were sold to cover tax withholding on vested RSUs, a common compensation-related transaction that does not indicate a change in corporate control or new trading strategy. Beneficial ownership after the transaction is reported as 118,936 shares held directly.

TL;DR: Transaction appears compliant and properly disclosed under Section 16; explanation and price range are provided.

The disclosure includes an explicit explanation that the sale satisfied tax withholding obligations from RSU vesting and provides a weighted-average price plus the inclusive price range. The filer also affirms willingness to provide granular price-by-price details upon request. The Form 4 was signed via attorney-in-fact, consistent with permitted filing practices. There are no indications of undisclosed agreements or derivative transactions in this filing.

09/04/2025 - 05:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WENTWORTH KORY JAMES

(Last)

(First)

(Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON

02210

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/02/2025		F		1,734⁽¹⁾	D	$5.4302⁽²⁾	118,936	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What transaction did Entrada Therapeutics (TRDA) report on this Form 4?

The CFO sold 1,734 shares on 09/02/2025 to cover tax withholding obligations related to vesting RSUs.

At what price were the shares sold according to the Form 4 for TRDA?

Weighted-average price $5.4302, with reported sale prices ranging between $5.36 and $5.58.

How many TRDA shares does the reporting person beneficially own after the sale?

118,936 shares beneficially owned following the reported transaction.

Why were the shares sold according to the filing?

The shares were sold to cover tax withholding obligations arising from the vesting of previously granted restricted stock units.

Who signed the Form 4 filing for the reporting person?

Signed by Jared Cohen as Attorney-in-Fact with the signature date shown as 09/04/2025.

AG真人官方

[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity

Insights

FAQ

What transaction did Entrada Therapeutics (TRDA) report on this Form 4?

At what price were the shares sold according to the Form 4 for TRDA?

How many TRDA shares does the reporting person beneficially own after the sale?

Why were the shares sold according to the filing?

Who signed the Form 4 filing for the reporting person?

NASDAQ:TRDA

TRDA Rankings

TRDA Latest News

TRDA Latest SEC Filings

TRDA Stock Data

AG真人官方

Trending News

[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity

Insights

Financial Analyst neutral

Compliance/Risk Analyst neutral

FAQ

What transaction did Entrada Therapeutics (TRDA) report on this Form 4?

At what price were the shares sold according to the Form 4 for TRDA?

How many TRDA shares does the reporting person beneficially own after the sale?

Why were the shares sold according to the filing?

Who signed the Form 4 filing for the reporting person?

NASDAQ:TRDA

TRDA Rankings

TRDA Latest News

TRDA Latest SEC Filings

TRDA Stock Data